Literature DB >> 15300228

Recovery of Valpha24+ NKT cells after hematopoietic stem cell transplantation.

K Haraguchi1, T Takahashi, K Hiruma, Y Kanda, Y Tanaka, S Ogawa, S Chiba, O Miura, H Sakamaki, H Hirai.   

Abstract

Human Valpha24+ natural killer T (NKT) cells have an invariant T-cell receptor-alpha chain and are activated in a CD1d-restricted manner. Valpha24+ NKT cells are thought to regulate immune responses and to play important roles in the induction of allograft tolerance. In this report, we analyzed the recovery of Valpha24+ NKT cells after hematopoietic stem cell transplantation and its correlation with graft-versus-host disease (GVHD). Patients who received a dose-reduced conditioning regimen, antithymocyte globulin- or CAMPATH-1H-containing conditioning regimen were excluded. NKT cells were reconstituted within 1 month after transplantation in peripheral blood stem cell transplantation recipients, while their numbers remained low for more than 1 year in bone marrow transplantation (BMT) recipients. The number of Valpha24+ NKT cells in BMT recipients with acute GVHD was lower than that in patients without acute GVHD, and both the CD4+ and CD4- Valpha24+ NKT subsets were significantly reduced. With regard to chronic GVHD, BMT recipients with extensive GVHD had significantly fewer Valpha24+ NKT cells than other patients. Furthermore, the number of CD4+ Valpha24+ NKT cells was also significantly reduced in patients with chronic extensive GVHD. Our results raise the possibility that the number of Valpha24+ NKT cells could be related to the development of GVHD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15300228     DOI: 10.1038/sj.bmt.1704582

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  23 in total

Review 1.  Application of natural killer T-cells to posttransplantation immunotherapy.

Authors:  Shin-ichiro Fujii
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

Review 2.  Potential role of natural killer cell receptor-expressing cells in immunotherapy for leukemia.

Authors:  Junji Tanaka; Masahiro Asaka; Masahiro Imamura
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

3.  Hematopoietic stem cell transplant effectively rescues lymphocyte differentiation and function in DOCK8-deficient patients.

Authors:  Bethany A Pillay; Danielle T Avery; Joanne M Smart; Theresa Cole; Sharon Choo; Damien Chan; Paul E Gray; Katie Frith; Richard Mitchell; Tri Giang Phan; Melanie Wong; Dianne E Campbell; Peter Hsu; John B Ziegler; Jane Peake; Frank Alvaro; Capucine Picard; Jacinta Bustamante; Benedicte Neven; Andrew J Cant; Gulbu Uzel; Peter D Arkwright; Jean-Laurent Casanova; Helen C Su; Alexandra F Freeman; Nirali Shah; Dennis D Hickstein; Stuart G Tangye; Cindy S Ma
Journal:  JCI Insight       Date:  2019-04-25

Review 4.  Bone marrow and the control of immunity.

Authors:  Ende Zhao; Huanbin Xu; Lin Wang; Ilona Kryczek; Ke Wu; Yu Hu; Guobin Wang; Weiping Zou
Journal:  Cell Mol Immunol       Date:  2011-10-24       Impact factor: 11.530

5.  NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs.

Authors:  Edward S Morris; Kelli P A MacDonald; Vanessa Rowe; Tatjana Banovic; Rachel D Kuns; Alistair L J Don; Helen M Bofinger; Angela C Burman; Stuart D Olver; Norbert Kienzle; Steven A Porcelli; Daniel G Pellicci; Dale I Godfrey; Mark J Smyth; Geoffrey R Hill
Journal:  J Clin Invest       Date:  2005-10-13       Impact factor: 14.808

Review 6.  Human invariant natural killer T cells: implications for immunotherapy.

Authors:  Tsuyoshi Takahashi; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2009-07-29       Impact factor: 2.490

7.  Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer.

Authors:  Yanni Zhu; Drake J Smith; Yang Zhou; Yan-Ruide Li; Jiaji Yu; Derek Lee; Yu-Chen Wang; Stefano Di Biase; Xi Wang; Christian Hardoy; Josh Ku; Tasha Tsao; Levina J Lin; Alexander T Pham; Heesung Moon; Jami McLaughlin; Donghui Cheng; Roger P Hollis; Beatriz Campo-Fernandez; Fabrizia Urbinati; Liu Wei; Larry Pang; Valerie Rezek; Beata Berent-Maoz; Mignonette H Macabali; David Gjertson; Xiaoyan Wang; Zoran Galic; Scott G Kitchen; Dong Sung An; Siwen Hu-Lieskovan; Paula J Kaplan-Lefko; Satiro N De Oliveira; Christopher S Seet; Sarah M Larson; Stephen J Forman; James R Heath; Jerome A Zack; Gay M Crooks; Caius G Radu; Antoni Ribas; Donald B Kohn; Owen N Witte; Lili Yang
Journal:  Cell Stem Cell       Date:  2019-09-05       Impact factor: 24.633

Review 8.  Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges.

Authors:  Madhav V Dhodapkar
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

9.  iNKT cells coordinate immune pathways to enable engraftment in nonconditioned hosts.

Authors:  Nicholas J Hess; Nikhila S Bharadwaj; Elizabeth A Bobeck; Courtney E McDougal; Shidong Ma; John-Demian Sauer; Amy W Hudson; Jenny E Gumperz
Journal:  Life Sci Alliance       Date:  2021-06-10

Review 10.  Harnessing Mechanisms of Immune Tolerance to Improve Outcomes in Solid Organ Transplantation: A Review.

Authors:  Priscila Ferreira Slepicka; Mahboubeh Yazdanifar; Alice Bertaina
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.